NEW YORK (GenomeWeb) – Transgenomic today priced its public offering of stock and warrants, expecting to raise $6.2 million in net proceeds. 

The firm is offering 3,573,899 shares of its common stock, as well as corresponding warrants to purchase 714,780 shares of its stock. The stocks and warrants will be sold in combination with one warrant to purchase .20 of a share of stock for each share of stock sold. The combined price for each share and corresponding warrant is $1.95, Transgenomic said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.